ProQR Therapeutics (PRQR) Non-Current Deferred Tax Liability (2022 - 2025)

ProQR Therapeutics' Non-Current Deferred Tax Liability history spans 3 years, with the latest figure at $3.2 million for Q4 2024.

  • For Q4 2024, Non-Current Deferred Tax Liability fell 21.81% year-over-year to $3.2 million; the TTM value through Dec 2024 reached $3.2 million, down 21.81%, while the annual FY2024 figure was $3.2 million, 21.23% down from the prior year.
  • Non-Current Deferred Tax Liability for Q4 2024 was $3.2 million at ProQR Therapeutics, down from $4.0 million in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $4.0 million in Q4 2023 and bottomed at $3.2 million in Q4 2024.
  • The 3-year median for Non-Current Deferred Tax Liability is $3.8 million (2022), against an average of $3.7 million.
  • The largest annual shift saw Non-Current Deferred Tax Liability grew 5.74% in 2023 before it fell 21.81% in 2024.
  • A 3-year view of Non-Current Deferred Tax Liability shows it stood at $3.8 million in 2022, then grew by 5.74% to $4.0 million in 2023, then dropped by 21.81% to $3.2 million in 2024.
  • Per Business Quant, the three most recent readings for PRQR's Non-Current Deferred Tax Liability are $3.2 million (Q4 2024), $4.0 million (Q4 2023), and $3.8 million (Q4 2022).